GILEAD SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.58 USD | -0.25% |
|
-3.56% | -16.74% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.75
USD
Average target price
86.26
USD
Spread / Average Target
+27.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.74% | 84.48B | |
| +27.91% | 676B | |
| +24.27% | 559B | |
| -7.49% | 356B | |
| +15.09% | 320B | |
| +5.18% | 286B | |
| +2.62% | 213B | |
| +0.15% | 207B | |
| -9.41% | 199B | |
| -8.01% | 142B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences : Morgan Stanley Adjusts Price Target on Gilead Sciences to $81 From $87, Maintains Overweight Rating
